ArticleTopics in antiviral medicine2019
Fatty liver disease in persons with HIV infection.
Article in Topics in antiviral medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- Plasma proteomics reveals markers of metabolic stress in HIV infected children with severe acute malnutrition.Scientific reports · 2020Trial
- Intestinal Microbiome, Fecal Fermentation Profile, and Health Indices in HIV-Positive Men Versus Normal Controls Without HIV.Nutrients · 2026Article
- Predicting MASLD in People With HIV Using Anthropometric Measures: A Multicenter Cross-Sectional Study.Open forum infectious diseases · 2026Article
- The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- HIV, Viral Hepatitis, and Schistosomiasis Association with Liver Cancer: A Systematic Review.Microorganisms · 2025Review
- Microbial translocation and gut damage is associated with hepatic fibrosis but not steatosis in women with and without HIV.AIDS (London, England) · 2025Article
- The Impact of Hepatitis B and/or C on Liver Function and on the Response to Antiretroviral Therapy in HIV-Infected Patients: A Romanian Cohort Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer.American journal of preventive cardiology · 2024Review
- Hepatic mitochondrial and peroxisomal alterations in acutely ill malnourished Malawian children: A postmortem cohort study.Global pediatrics · 2024Article
- Cardiometabolic Characteristics of Obesity Phenotypes in Persons With HIV.Open forum infectious diseases · 2024Article
- Liver Steatosis is Prevalent in Lean People With HIV and Associated With Exposure to Antiretroviral Treatment-A Cross-sectional Study.Open forum infectious diseases · 2024Article
- Risk Stratification of Advanced Fibrosis in Patients With Human Immunodeficiency Virus and Hepatic Steatosis Using the Fibrosis-4, Nonalcoholic Fatty Liver Disease Fibrosis, and BARD Scores.Open forum infectious diseases · 2024Article
- Risk of hepatocellular carcinoma in people with HIV in the United States, 2001-2019.Journal of the National Cancer Institute · 2024Article
- Non-alcoholic fatty liver disease among people living with HIV on long-term antiretroviral therapy in Indonesia: Prevalence and related factors.SAGE open medicine · 2024Article
- Impact of Combination Antiretroviral Treatment on Liver Metabolic Health in HIV-Infected Persons.Viruses · 2023Review
- Prevalence and dynamics of NAFLD-associated fibrosis in people living with HIV in Vienna from first presentation to last follow-up.Wiener klinische Wochenschrift · 2023Article
- The Role of Gut Dysbiosis in the Loss of Intestinal Immune Cell Functions and Viral Pathogenesis.Microorganisms · 2023Review
- Risk Stratification of Advanced Fibrosis in HIV Patients With Hepatic Steatosis Using the NAFLD Fibrosis and BARD Scores.medRxiv : the preprint server for health sciences · 2023Article
- Nutritional and Lifestyle Therapy for NAFLD in People with HIV.Nutrients · 2023Review
- Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus Coinfection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The leading cause of non-HIV-related mortality is liver disease. Fatty liver disease can be characterized as alcoholic or nonalcoholic in nature. Alcohol use is prevalent among individuals with HIV infection and can lead to medication nonadherence, lower CD4+ cell count, inadequate viral suppression, and disease progression. The pathogenesis of nonalcoholic fatty liver disease (NAFLD) in individuals with HIV infection includes metabolic syndrome, hyperuricemia, HIV-related lipodystrophy, genetic polymorphisms, medications, HIV itself, and the gut microbiome. The prevalence of NAFLD in persons with HIV infection ranges from 30% to 65% depending on the modality of diagnosis. Individuals with HIV infection and NAFLD are at higher risk of cardiovascular disease; however, there is a dearth of longitudinal outcomes studies on this topic. Current therapies for NAFLD, such as vitamin E and pioglitazone, have not been studied in persons with HIV infection. There are several drugs in phase II and III clinical trials that specifically target NAFLD in HIV, including CC chemokine receptor 5 inhibitors, growth hormone-releasing factor agonists, and stearoyl-CoA desaturase inhibitors. Persons with HIV should be screened for NAFLD while pursuing aggressive risk factor modification and lifestyle changes, given the increased risk of cardiovascular mortality.
Indexed as
Identifiers
31136997PMC6550355W2992656324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.